ro13-9904 and Muscular-Diseases

ro13-9904 has been researched along with Muscular-Diseases* in 2 studies

Reviews

1 review(s) available for ro13-9904 and Muscular-Diseases

ArticleYear
Pyomyositis in the acquired immunodeficiency syndrome.
    Southern medical journal, 2000, Volume: 93, Issue:3

    Pyomyositis, a purulent infection of skeletal muscle, is usually caused by Staphylococcus aureus. Many cases of pyomyositis in human immunodeficiency virus (HIV) seronegative patients have been reported in North America and have been reviewed extensively. Moreover, pyomyositis has been reported in association with HIV infection in patients with or without the acquired immunodeficiency syndrome (AIDS). We describe two patients with pyomyositis and HIV and review the available English language literature. Leukocytosis and bacteremia tend to occur less frequently in those with HIV infection and pyomyositis. However, fever, S aureus infection, and bilateral involvement occur more frequently in HIV-positive patients. Antibiotic therapy together with surgical drainage or aspiration is usually sufficient.

    Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Bacteremia; Cefazolin; Ceftriaxone; Cephalosporins; Drainage; Follow-Up Studies; HIV Infections; Humans; Leukocytosis; Male; Muscle, Skeletal; Muscular Diseases; Staphylococcal Infections; Staphylococcus aureus; Vancomycin

2000

Trials

1 trial(s) available for ro13-9904 and Muscular-Diseases

ArticleYear
Ceftriaxone as short-term antimicrobial chemoprophylaxis in orthopedic surgery: a 1-year multicenter follow-up. Preliminary results of a controlled multicentre study.
    European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 1989, Volume: 21 Suppl 1

    In this multicentre study, 883 evaluable patients undergoing orthopedic surgery were randomly assigned to receive antiinfective prophylaxis with either ceftriaxone (Rocephin) or cefamandole. 25 patients in the ceftriaxone group and 29 patients in the cefamandole group (5.6 vs 6.5%) presented with infectious complications within the first 60 days after surgery. Delayed deep wound infections developed in only 1 of 435 patients in the ceftriaxone group compared with 4 of 413 patients in the cefamandole group. Both drugs were well tolerated. The infection rate was twice as high after surgery in conventional operating theatres than after treatment in hypersterile operating theatres (3.3 vs 6.5%); this difference is not statistically significant.

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Bone Diseases; Cefamandole; Ceftriaxone; Child; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Muscular Diseases; Postoperative Complications; Premedication

1989